Background:
@EN Previous agar dilution test showed that cefepime is very active against various gram-negative bacilli including the third generation cephalosporin-resistant Enterobacter, Serratia and Citrobacter. The aim of this study was to test the
susceptibility
of large number of recent clinical isolates of gram-negative bacilli to cefepime.
@ES Methods:
@EN A total of 4797 isolates of Enterobacteriaceae, Aeromonas, Pseudomonas aeruginosa, Acinetobacter baumannii and Xanthomonas maltophilia isolated from a tertiary-care general hospital patients, were tested by the NCCLS disk diffusion test and
the
results were analyzed using a WHONET Ⅲ program.
@ES Results:
@EN Resistance rates of Enterobacteriaceae were 82% to ampicillin, 71% to cephalothin, 24% to gentamicin, 10% to ofloxacin. 15% to cefotaxime, 7% to cefoperazone/sulbactam and 1% to cefepime. P. aeruginosa showed the lowest resistance rate of 24%
to
both cefepime and ceftazidime. The cefepime susceptible rates of cefotaxime-resistant isolates were C. freundii 77% E. cloacae 61% and S. marcescens 53%.
@ES Conclusion:
@EN Resistance rates of the recent clinical isolates of aerobic gram-megative bacilli, including the third generation cephalosporin-resistant nosocomial pathogens, are lower to cefepime than to the other antimicrobial agents compared.
|